This increased DNA-PK activity is a consequence of either a variation in the DNA-end binding activity of the Ku heterodimer, the presence of a variant form of it [75], or, as identified in CLL patients, a specific phosphorylated form of Ku70 (i.e., on serine 33) [76]. Here, PRKDC is linked to B-cell chronic lymphocytic leukemia.